Deep brain stimulation is a promising treatment for neuropsychiatric conditions such as major depression. It could be optimized by identifying neural biomarkers that trigger therapy selectively when symptom severity is elevated. We developed an approach that first used multi-day intracranial electrophysiology and focal electrical stimulation to identify a personalized symptom-specific biomarker and a treatment location where stimulation improved symptoms. We then implanted a chronic deep brain sensing and stimulation device and implemented a biomarker-driven closed-loop therapy in an individual with depression. Closed-loop therapy resulted in a rapid and sustained improvement in depression. Future work is required to determine if the results and approach of this n-of-1 study generalize to a broader population.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
The data that support the findings in this article are available within the article itself, the source data and within our publicly available GitHub repository. Raw neural signals are freely available from the corresponding author upon request. The data used to produce the results and figures in this paper are available at https://github.com/ScangosLab/closed_loop_mdd. Source data are provided with this paper.
The code used to produce the results and figures in this paper is available at https://github.com/ScangosLab/closed_loop_mdd.
Howland, R. H. Sequenced Treatment Alternatives to Relieve Depression (STAR*D). Part 2: study outcomes. J. Psychosoc. Nurs. Ment. Health Serv. 46, 21–24 (2008).
Holtzheimer, P. E. et al. Subcallosal cingulate deep brain stimulation for treatment-resistant depression: a multisite, randomised, sham-controlled trial. Lancet Psychiatry 4, 839–849 (2017).
Dougherty, D. D. et al. A randomized sham-controlled trial of deep brain stimulation of the ventral capsule/ventral striatum for chronic treatment-resistant depression. Biol. Psychiatry 78, 240–248 (2015).
Bergfeld, I. O. et al. Deep brain stimulation of the ventral anterior limb of the internal capsule for treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry 73, 456–464 (2016).
Williams, L. M. Precision psychiatry: a neural circuit taxonomy for depression and anxiety. Lancet Psychiatry 3, 472–480 (2016).
Bouthour, W. et al. Biomarkers for closed-loop deep brain stimulation in Parkinson disease and beyond. Nat. Rev. Neurol. 15, 343–352 (2019).
Scangos, K. W., Makhoul, G. S., Sugrue, L. P., Chang, E. F. & Krystal, A. D. State-dependent responses to intracranial brain stimulation in a patient with depression. Nat. Med. 27, 229–231 (2021).
Keller, C. J. et al. Mapping human brain networks with cortico-cortical evoked potentials. Philos. Trans. R. Soc. Lond. B Biol. Sci. 369, 20130528 (2014).
Sun, F. T. & Morrell, M. J. The RNS System: responsive cortical stimulation for the treatment of refractory partial epilepsy. Expert Rev. Med. Devices 11, 563–572 (2014).
Giorgino, T. Computing and visualizing dynamic time warping alignments in R: the dtw package. J. Stat. Softw. 31 (2009).
Price, J. L. & Drevets, W. C. Neurocircuitry of mood disorders. Neuropsychopharmacology 35, 192–216 (2010).
Kirkby, L. A. et al. An amygdala-hippocampus subnetwork that encodes variation in human mood. Cell 175, 1688–1700.e14 (2018).
Malone, D. A. Jr. et al. Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression. Biol. Psychiatry 65, 267–275 (2009).
Mayberg, H. S. et al. Deep brain stimulation for treatment-resistant depression. Neuron 45, 651–660 (2005).
Haq, I. U. et al. Smile and laughter induction and intraoperative predictors of response to deep brain stimulation for obsessive-compulsive disorder. Neuroimage 54, S247–S255 (2011).
Dunner, D. L. et al. Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. J. Clin. Psychiatry 67, 688–695 (2006).
Waltz, E. Green light for deep brain stimulator incorporating neurofeedback. Nat. Biotechnol. 38, 1014–1015 (2020).
Riva-Posse, P. et al. Defining critical white matter pathways mediating successful subcallosal cingulate deep brain stimulation for treatment-resistant depression. Biol. Psychiatry 76, 963–969 (2014).
Campbell, M. C. et al. Mood response to deep brain stimulation of the subthalamic nucleus in Parkinson’s disease. J. Neuropsychiatry Clin. Neurosci. 24, 28–36 (2012).
Timmerby, N., Andersen, J. H., Søndergaard, S., Østergaard, S. D. & Bech, P. A systematic review of the clinimetric properties of the 6-item version of the Hamilton Depression Rating Scale (HAM-D6). Psychother. Psychosom. 86, 141–149 (2017).
Salloum, N. C. et al. Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. Depress. Anxiety 36, 235–243 (2019).
Yeung, A. W. K. & Wong, N. S. M. The historical roots of visual analog scale in psychology as revealed by reference publication year spectroscopy. Front. Hum. Neurosci. 13, 86 (2019).
Harris, P. A. et al. The REDCap consortium: building an international community of software platform partners. J. Biomed. Inform. 95, 103208 (2019).
Harris, P. A. et al. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inform. 42, 377–381 (2009).
Chang, E. F. Towards large-scale, human-based, mesoscopic neurotechnologies. Neuron 86, 68–78 (2015).
Matsumoto, R. et al. Functional connectivity in the human language system: a cortico-cortical evoked potential study. Brain 127, 2316–2330 (2004).
Rao, V. R. et al. Direct electrical stimulation of lateral orbitofrontal cortex acutely improves mood in individuals with symptoms of depression. Curr. Biol. 28, 3893–3902.e4 (2018).
Schiff, S. J., Aldroubi, A., Unser, M. & Sato, S. Fast wavelet transformation of EEG. Electroencephalogr. Clin. Neurophysiol. 91, 442–455 (1994).
Friston, K. J. Functional and effective connectivity: a review. Brain Connect. 1, 13–36 (2011).
Bassett, D. S. & Sporns, O. Network neuroscience. Nat. Neurosci. 20, 353–364 (2017).
Khambhati, A. N. et al. Functional control of electrophysiological network architecture using direct neurostimulation in humans. Netw. Neurosci. 3, 848–877 (2019).
Riva-Posse, P. et al. A connectomic approach for subcallosal cingulate deep brain stimulation surgery: prospective targeting in treatment-resistant depression. Mol. Psychiatry 23, 843–849 (2018).
Choi, K. S., Riva-Posse, P., Gross, R. E. & Mayberg, H. S. Mapping the “depression switch” during intraoperative testing of subcallosal cingulate deep brain stimulation. JAMA Neurol. 72, 1252–1260 (2015).
Sokolov, A. A. et al. Linking structural and effective brain connectivity: structurally informed Parametric Empirical Bayes (si-PEB). Brain Struct. Funct. 224, 205–217 (2019).
Mori, S. & van Zijl, P. C. Fiber tracking: principles and strategies—a technical review. NMR Biomed. 15, 468–480 (2002).
Rabiner, L. R & Juang, B. H. Fundamentals of Speech Recognition (PTR Prentice Hall, 1993).
Sakoe, H. & Chiba, S. Dynamic programming algorithm optimization for spoken word recognition. IEEE Trans. Acoust. 26, 43–49 (1978).
This work was supported by a National Institutes of Health award no. K23NS110962 (K.W.S.), NARSAD Young Investigator grant from the Brain & Behavior Research Foundation (K.W.S.), 1907 Trailblazer Award (K.W.S.) and a Ray and Dagmar Dolby Family Fund through the Department of Psychiatry at UCSF (K.W.S., A.D.K., E.F.C., L.P.S., A.N.K., P.M.S., G.S.M., H.Z., T.X.L., V.R.R., K.K.S. and H.E.D.).
A.D.K. consults for Eisai, Evecxia Therapeutics, Ferring Pharmaceuticals, Galderma, Harmony Biosciences, Idorsia, Jazz Pharmaceuticals, Janssen Pharmaceuticals, Merck, Neurocrine Biosciences, Pernix Pharma, Sage Therapeutics, Takeda Pharmaceutical Company, Big Health, Millennium Pharmaceuticals, Otsuka Pharmaceutical and Neurawell Therapeutics. A.D.K. acknowledges support from Janssen Pharmaceuticals, Jazz Pharmaceuticals, Axsome Therapeutics (no. AXS-05-301) and Reveal Biosensors. K.W.S. serves on the advisory board of Nesos. UCSF and E.F.C. have patents related to brain stimulation for the treatment of neuropsychiatric disorders. V.R.R. has served as a paid consultant for NeuroPace but declares no targeted funding from NeuroPace for this study. P.A.S. receives research support from Medtronic. The other authors declare no competing interests.
Peer review information Nature Medicine thanks Ziv Williams and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Jerome Staal was the primary editor on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
a. Biomarker identification was performed at two levels of spatial resolution (see also Fig. 1c). In the brain region level model, spectral power was averaged across all contacts within brain regions (60 features). Top neural features (defined by F-score, ANOVA) that discriminated high vs. low symptom severity states are shown. Gamma power in the bilateral AMY, right OFC, left SGC, and right HPC had high state discriminative potential (Accuracy: mean 0.73, std 0.08; AUC: mean 0.76, std 0.10). ROC curves reflect mean ± SEM over n=1000 randomly sampled features for the true model (blue) and the shuffled model (gray). b. Evoked potentials (z-scored relative to baseline) across the corticolimbic network due to single pulse stimulation in the right VC/VS, OFC and SGC is shown overlayed on brain as heatmap. Warmer colors indicate a larger N1 amplitude. c. Location of right sided sEEG leads targeting AMY (pink), VC/VS (orange), SGC (green), and OFC (blue). Fiber tracts (color coded by orientation) show putative structural connections between candidate pairs of stimulation and sensing contacts (VC/VS-AMY, VC/VS-OFC, SGC-AMY, OFC-AMY) from deterministic tractography using 3 mm ROIs centered on each contact. Tractography parameters were the same for all pairs: minimum FA = 0.1; minimum fiber length = 80 mm; maximum angulation = 20 degrees.
Multimodal method for personalized responsive stimulation multi-lead targeting began with clinical mapping to identify candidate sites where stimulation reliably led to symptom improvement across a range of doses and symptom severity states. Candidate sensing locations were identified by pairing resting state neural activity with symptom severity ratings to identify spectral power biomarkers that correlated with depression. The relationship between candidate stimulation and sensing targets were then tested using three approaches. First, effective network connectivity was assessed by examining the evoked response at nodes across the network due to single pulse stimulation at candidate targets. Second, structural connectivity between candidate contact pairs was assessed using tractography. Influential tracts were identified to help with retargeting during implantation of chronic stimulation device. Finally, the feasibility of closed-loop control was assessed by examining the effect of stimulation in candidate stimulation sites on putative biomarkers identified in candidate sensing locations. This personalized approach enabled us to identify one best stimulation and sensing target pair which were then utilized for the implantation of the RNS System and delivery of closed-loop neurostimulation therapy.
About this article
Cite this article
Scangos, K.W., Khambhati, A.N., Daly, P.M. et al. Closed-loop neuromodulation in an individual with treatment-resistant depression. Nat Med 27, 1696–1700 (2021). https://doi.org/10.1038/s41591-021-01480-w